{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"199.5","value":"24"},{"groupId":"OG001","spread":"200.1","value":"28"},{"groupId":"OG002","spread":"236.3","value":"54"}]}],"title":"C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.59","value":"30"},{"groupId":"OG001","spread":"52.7","value":"43.4"},{"groupId":"OG002","spread":"55.21","value":"65"}]}],"title":"C1D8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"An ex vivo assay (utilized in monotherapy only), Measuring Total c-Myc protein expressed from an exogenously added cell line (KMS12BM) to patient plasma, before and after administration of INCB057643.","dispersionType":"Standard Error","groups":[{"description":"cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the Part 1 TGA,TGB,TGC.","id":"OG000","title":"8mg QD INCB057643"},{"description":"12mg QD INCB057643 Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the Part 1 TGA,TGB, and Part 2 TGA,TGB.","id":"OG001","title":"12mg QD INCB057643"},{"description":"Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the Part 1 TGA","id":"OG002","title":"16mg QD INCB057643"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"PD in plasma at pre-dose and 0.5, 1, 2, 4, 6 and 8 hours postdose, for C1D1 and C1D8, and 24hrs post dose for C1D1","title":"Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administration of INCB057643 When Administered as Monotherapy in an Ex-vivo Assay","type":"SECONDARY","unitOfMeasure":"%Inhibition of Total c-Myc"}